The proteasome inhibitor bortezomib (BTZ), which is an antineoplastic agent already approved and commercialized for the treatment of multiple myeloma and mantle-cell lymphoma [393], is an eligible candidate for this function; data regarding its relation to the anti-GBM activity of NK cells have been reported recently by Navarro et al. (2019) [161] and Luna et al. (2019) [394]; both studies showed that primary GBM cell lines, when treated with BTZ, had a significantly increased membrane expression of ligands for the NK-activating receptor NKG2D, and also for the death receptor TRAIL-R2. This evidence concerns the gene TNFRSF10B and glioblastoma.